focus -WSS

focus

author：hotspot 2025-10-01 23:01:50 - browse：5

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Hospitals are dialing back on venture capital investing

WSS

Senators push IRS to launch nonprofit hospital probe

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Novo Nordisk touts Wegovy study, but still struggling with supply

Risky weight loss products often used by teens globally, per study

Maui wildfire now ranks as the fifth

YouTube cracks down on misinformation on cancer treatment

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Megan Rapinoe shares emotional post following US Women's World Cup exit

Medical leaders decry Supreme Court decision on affirmative action

DeSantis can now import cheaper drugs. But will Biden get credit?

Affirmative action in medical school literally saved lives

Dozens dead from Maui wildfires: What we know about the victims

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Psychedelics group wrestles with new pharma identity

Generative AI mines health records to identify patients’ social needs

explore

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Judge sides with young activists in first

Designating disabled people as health disparity population is crucial

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Biotech reporter’s notebook: A sunnier mood at JPM 2024

hotspot

hotspot

explore

focus